Introducing
A/Prof Tomas Kalincik
Hello, I’m Tomas, Head of the Clinical Outcomes Research (CORe) Unit.
a little bit about me
I am the Head of the CORe Unit at the University of Melbourne, as well as the Head of the Multiple Sclerosis and Neuroimmunology Service at the Royal Melbourne Hospital.
Together with the CORe team, I specialise in analytics of observational data in neurology. I am an active participant in the global MSBase collaboration, undertaking a role in the MSBase Scientific Leadership Group.
My research interests revolve around disease outcomes in multiple sclerosis and Neuromyelitis Optica. These comprise comparative treatment effectiveness, management of treatment failure, individual treatment response, personalised therapy, prognostics, epidemiology and utility of volumetric MRI.
Publications
- The MSBase registry: Informing clinical practice.
- Effectiveness of oral multiple sclerosis therapies in clinical context.
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.
- Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
- Where there is inflammation, treatment may reduce disability progression - Yes.
- Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
- Defining secondary progressive multiple sclerosis.
- Observational data: Understanding the real MS world.
- Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
- Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
- Data quality evaluation for observational multiple sclerosis registries.
- Olfactory ensheathing cells but not fibroblasts reduce the duration of autonomic dysreflexia in spinal cord injured rats.
- Treatment decisions in multiple sclerosis - insights from real-world observational studies.
- Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis.
- Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.
- Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
- Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
- Olfactory ensheathing cells reduce duration of autonomic dysreflexia in rats with high spinal cord injury.
- Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
- Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
- Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis.
- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
- Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.
- Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
- Comparisons of therapies in different scenarios help complete the puzzle.
- Risk of relapse phenotype recurrence in multiple sclerosis.
- Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.
- Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data.
- Comparative efficacy of switching to natalizumab in active multiple sclerosis.
- Thalamic atrophy is associated with development of clinically definite multiple sclerosis.
- Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review.
- Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.
- Reporting treatment outcomes in observational data: A fine balance.
- Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.
- Defining reliable disability outcomes in multiple sclerosis.
- Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
- The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
- Contribution of different relapse phenotypes to disability in multiple sclerosis.
- Predictors of disability worsening in clinically isolated syndrome.
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
- Fingolimod after natalizumab and the risk of short-term relapse.
- Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
- Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
- Familial mesial temporal lobe epilepsy and the borderland of déjà vu.
- Disturbance of real space navigation in moderately advanced but not in early Huntington's disease.
- Stop inflammation and you stop neurodegeneration in MS - NO.